



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 8189)

SUSPENSION OF TRADING

At the request of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”), trading in the H shares of the Company on the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited will be suspended with effect from 9:30 a.m. on Tuesday, 18 November 2008 pending the release of an announcement in relation to the placing of new H shares of the Company, which is price-sensitive in nature.

By order of the board of
Tianjin TEDA Biomedical Engineering Company Limited
Wang Shuxin
Chairman

Hong Kong, 18 November 2008

As at the date of this announcement, the Board comprises of three executive Directors, being Mr. Wang Shuxin, Mr. Xie Kehua and Mr. Zhang Songhong; three non-executive Directors, being Mr. Feng Enqing, Mr. Xie Guangbei and Mr. Wang Xiaofa and three independent non-executive Directors, being Professor Xian Guoming, Mr. Wu Chen and Mr. Guan Tong.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

The announcement will remain on the GEM website at <http://www.hkgem.com> at the “Latest Company Announcements” page for 7 days from the date of its publication.